Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Intrauterine Fetal Death
Brief Summary: Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements.

Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.


Options:
A: Inclusion Criteria:

* All women above 18 years of age
* Less than 12 weeks of gestation.
* Pregnancy is confirmed by pregnancy test or ultrasound scan.
* missed abortion
* Normal general and gynecological examination.
* The size of the uterus on pelvic examination was compatible with the estimated duration of pregnancy

Exclusion Criteria:

* Hemodynamically unstable.
* Suspected sepsis with temperature 38 °C.
* Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism, respiratory illnesses, recent liver disease or pruritus of pregnancy.
* Presence of intrauterine contraceptive device (IUCD).
* Suspect or proven ectopic pregnancy.
* Failed medical or surgical evacuation before presentation.
* Known allergy to misoprostol.
B: Inclusion Criteria:

1. Women with confirmed incomplete induced miscarriage, less than 12 weeks' gestation.
2. No known allergy to misoprostol.
3. Women who will be haemodynamically stable.
4. Good access to emergency facilities. Exclusion

1. Women with signs of severe infection ( fever \> 38°) 2. Women with severe vaginal bleeding 3. Women known to have allergy to prostaglandins 4. Severe abdominal pain requiring immediate intervention
C: Inclusion Criteria:

* Major, under 45 years with intrauterine trophoblastic retention after incomplete miscarriage in the first quarter (termination of pregnancy \< 14 WA),
* With desire of pregnancy ;
* Intrauterine trophoblastic retention diagnosed by transvaginal pelvic ultrasound finding a intrauterine heterogeneous image or intrauterine gestational sac more than 15 mm in thickness, complicated or not of endometritis ;
* Decision to surgical management of incomplete miscarriage by the health care team ;
* Patient beneficiary or affiliated to a health insurance
* Informed and signed consent

Exclusion Criteria:

Will not be included in the protocol patients :

* having a uterine malformation known ;
* having received surgical treatment for the current intrauterine retention ;
* with intrauterine retention diagnosed by transvaginal pelvic ultrasound of more than 50 mm in thickness ;
* requiring a haemostatic act in urgency for heavy vaginal bleeding (miscarriage haemorrhage) ;
* bearer of intrauterine device ;
* having an evolutive pregnancy;
* having an ectopic pregnancy;
* having a trophoblastic retention following a voluntary abortion ;
* having a pregnancy achieved by medically assisted procreation
D: Inclusion Criteria:

* 14 and 24 weeks of gestation
* Both nulliparous and multiparous women
* An unfavorable cervix (Bishop's score less than 8)

Exclusion Criteria:

* Known contraindications to the use of prostaglandins (e.g. asthma)
* Previous uterine scar (previous cesarean or myomectomy where the endometrial cavity was entered)

Answer: D